Emerging role of novel combinations for induction therapy in multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 7, Issue 1, 2006, Pages 33-41

  Voorhees, Peter M ^a   Orlowski, Robert Z ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow microenvironment; Bortezomib; Chemotherapy resistance; Lenalidomide; Pegylated liposomal doxorubicin; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; AMOXICILLIN; ANTHRACYCLINE; BORTEZOMIB; CISPLATIN; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; PROTEASOME INHIBITOR; THALIDOMIDE; VALACICLOVIR; VINCRISTINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; KIDNEY FAILURE; LUNG EMBOLISM; MULTIPLE MYELOMA; MUSCLE WEAKNESS; MYALGIA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PNEUMONIA; REVIEW; SENSORY NEUROPATHY; SEPTIC SHOCK; SKIN TOXICITY; SOMNOLENCE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 33748305704     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.037     Document Type: Review

References (66)

1. Alexanian R, Bonnet J, Gehan E, et al. Combination chemotherapy for multiple myeloma. Cancer 1972; 30:382-389.
2. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialist's Collaborative Group. J Clin Oncol 1998; 16:3832-3842.
3. Facon T, Mary JY, Pegourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006; 107:1292-1298.
4. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335:91-97.
5. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.
6. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
7. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4:314-322.
8. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082-4085.
9. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87:503-508.
10. Vacca A, Di Loreto M, Ribatti D, et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol 1995; 50:9-14.
11. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93:3064-3073.
12. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
13. Hideshisna T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96:2943-2950.
14. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98:210-216.
15. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99:4525-4230.
16. Hardin J, MacLeod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84:3063-3070.
17. Lichtenstein A, Tu Y, Fady C, et al. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995; 162:248-255.
18. Alexanian R, Weber D, Anagnostopoulos A, et al. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 2003; 40:3-7.
19. Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121:768-771.
20. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12:991-995.
21. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319-4323.
22. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-19.
23. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89:826-831.
24. Abdelkefi A, Torjman L, Beri Romdhane N, et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (< 61 years) with symptomatic multiple myeloma. Bone Marrow Transplant 2005; 36:193-198.
25. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106:35-39.
26. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431-436.
27. Rajkumar S, Hussein M, Catalano J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma. Presented at: 2006 Annual Meeting of American Society of Clinical Oncology; June 2-6, 2006; Atlanta, GA. Abstract #7517.
28. Palumbo A, Bertola A, Musto P, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 2005; 104:1428-1433.
29. Palumbo A, Bringhen S, Musto P, et al. Oral melphalan, prednisone, and thalidomide for multiple myeloma. Blood 2005; 106:230a (Abstract #779).
30. Facon T, Mary JY, Hulin C, et al. Major superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood 2005; 106:230a (Abstract #780).
31. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274:784-787.
32. Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276:22382-22387.
33. Schutt P, Ebeling P, Buttkereit U, et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 2005; 74:40-46.
34. Chanan-Khan A, Miller KC, McCarthy P, et al. VAD-t (vincristine, adriamycin, dexamethasone, and low-dose thalidomide) is an effective initial therapy with high response rates for patients with treatment naive multiple myeloma (MM). Blood 2004; 104:943a (Abstract #3463).
35. Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004; 15:134-138.
36. Agrawal N, Hussein MA, Elson P, et al. Pegylated doxorubicin (D), vincristine (V), reduced frequency dexamethasone (d) and thalidomide (T) (DVdT) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients. Blood 2003; 102:237a (Abstract #831).
37. Almhanna K, Suppiah R, Baz R, et al. Doxil, vincristine, reduced frequency dexamethasone in combination with thalidomide (DVd-T) is associated with higher overall and progression free survival as compared to DVd in patients with multiple myeloma (MM). Blood 2005; 106:718a (Abstract #2557).
38. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354:1021-1030.
39. Attal M, Harousseau J-L, Leyvraz S, et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma: final analysis of a prospective randomized study of the "Intergroupe Francophone du Myelome." Blood 2005; 106:335a (Abstract #1148).
40. Goldschmidt H, Sonneveld P, Breitkrenz I, et al. HOVON 50/GMMGHD3-Trial: phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years. Blood 2005; 106:128a (Abstract #424).
41. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100:3063-3067.
42. Dimopoulos M, Weber D, Chen C, et al. Evaluating oral lenalidomide (Revlimid) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 2005; 90:160 (Abstract #0402).
43. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-4053.
44. Niesvizky R, Pekle K, Gelbshtein U, et al. BiRD (Biaxin® /Revlimid®/ dexamethasone) combination therapy (Rx) results in high complete remissions (CR) and overall responses in myeloma (MM) with poor prognostic features. Blood 2005; 106:190a (Abstract #642).
45. Palumbo A, Falco P, Musto P, et al. Oral Revlimid® plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma. Blood 2005; 106:231a (Abstract #785).
46. Voorhees PM, Dees EC, O'Neil B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9:6316-6325.
47. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-2622.
48. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-3076.
49. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62:4996-5000.
50. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101:2377-2380.
51. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9:1136-1144.
52. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20:4420-4427.
53. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
54. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498.
55. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776-783.
56. Harousseau J-L, Attal M, Leleu X, et al. Bortezomib (Velcade®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study. Blood 2004; 104:416a (Abstract #1490).
57. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105:3058-3065.
58. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/ bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129:755-762.
59. Popat R, Oakervee HE, Curry N, et al. Reduced dose PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood 2005; 106:717a (Abstract #2554).
60. Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24:937-944.
61. Mateos M, Hernandez J, Mediavilla J, et al. A phase I/II national, multicenter, open-label study of bortezomib plus melphalan and prednisone in elderly untreated multiple myeloma (MM) patients. Blood 2005; 106:232a (Abstract #786).
62. Zangari M, Barlogie B, Burns MJ, et al. Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T. Blood 2005; 106:717a (Abstract #2552).
63. Wang M, Delasalle K, Giralt S, et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood 2005; 106:231a (Abstract #784).
64. R (V) into upfront management of multiple myeloma (MM): comparison with TT2 + thalidomide (T). Blood 2005; 106:337a (Abstract #1154).
65. Cottler-Fox M, Holley D, Whigham L, et al. Hematopoietic progenitor cell (HPC) mobilization after initial therapy of multiple myeloma including Velcade: ability to collect HPC as a function of Velcade dosing. Blood 2004; 104:788a (Abstract #2884).
66. Richardson P, Chanan-Khan A, Schlossman R, et al. A multicenter phase II trial of bortezomib in patients with previously untreated multiple myeloma: efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy. Blood 2005; 106:716a (Abstract #2548).